Press Releases

Press Releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools.

Apr 16, 2014
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN) invites investors and the general public to its Annual Meeting of Stockholders to begin at 5:00 p.m. ET on Wednesday, April 23, 2014. The meeting will be held at the company's headquarters located at 3 Forbes Road, Lexington, MA 02421.
Mar 26, 2014
Agenus Inc. (Nasdaq: AGEN) today announced that Robert Stein, MD, PhD, Chief Scientific Officer of Agenus, will be presenting on Agenus’ checkpoint modulator portfolio and immuno-oncology strategy at the 4th Annual Cancer Immunotherapy Conference at the New York Academy of Medicine in New York
Mar 05, 2014
Agenus Reports Fourth Quarter and Full Year 2013 Financial Results LEXINGTON, Mass.--( BUSINESS WIRE )-- Agenus Inc. (NASDAQ: AGEN), a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants,
Mar 05, 2014
Novel checkpoint modulator antibodies include two GITR agonists and a CTLA-4 antagonist Selections made in strategic collaboration with Ludwig Cancer Research Ludwig Cancer Research and Agenus Inc. (NASDAQ: AGEN) today announced the selection of three monoclonal antibody checkpoint modulators
Feb 13, 2014
Agenus gains powerful platform for rapid discovery and optimization of fully-human antibodies against a wide array of molecular targets Agenus Inc. (Nasdaq: AGEN), a biopharmaceutical company developing novel immunotherapeutics, including a portfolio of checkpoint modulators (CPMs), anti-cancer
Feb 06, 2014
Agenus Inc. (Nasdaq: AGEN), a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced that the company will be presenting at the 16th Annual BIO CEO & Investor Conference on Monday, February 10th at 9:30 am EST in the Conrad
Feb 05, 2014
Agenus Inc. (Nasdaq: AGEN) today announced the pricing of an underwritten public offering of 19,335,653 primary shares of its common stock at a price of $2.70 per share. Agenus has granted the underwriters a 30-day option to purchase up to 2,900,347 additional shares of common stock to cover
Jan 13, 2014
Agenus Inc. (Nasdaq: AGEN) a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced the appointment of Robert B. Stein, M.D., Ph.D., to the newly-created position of Chief Scientific Officer (CSO). Dr.
Oct 24, 2013
Agenus to host conference call beginning at 11 a.m. ET today LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), a biotechnology company working to develop novel immunology based treatments for cancers and infectious diseases, today announced its financial results and business
Sep 23, 2013
Agenus Inc. (Nasdaq: AGEN) today announced the closing of its previously announced agreement to sell $10 million of shares of its common stock, together with warrants to purchase additional shares of its common stock, in a registered direct offering to institutional investors.